In models of breast and colon carcinoma as well as melanoma, an anti-MARCO monoclonal antibody has been developed and has exhibited anti-tumor effects in some cases through reprogramming TAMs to pro-inflammatory phenotypes and enhancing tumor immune responses 198. This evidence concerns the gene MARCO and neoplasm.